← Back to Search

Monoclonal Antibodies

JNJ-77242113 for Plaque Psoriasis (FRONTIER 1 Trial)

Phase 2
Waitlist Available
Research Sponsored by Janssen Research & Development, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 weeks
Awards & highlights

FRONTIER 1 Trial Summary

This trial is testing a new medication for plaque psoriasis to see how well it works.

Eligible Conditions
  • Plaque Psoriasis

FRONTIER 1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 16
Secondary outcome measures
Serum albumin, bovine
Change from Baseline in PASI Total Score at Week 16
Change from Baseline in PSSD Signs Score at Week 16
+12 more

FRONTIER 1 Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: Group 5: JNJ-77242113 Dose 3 BID and PlaceboExperimental Treatment2 Interventions
Participants will receive JNJ-77242113 Dose 3 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Group II: Group 4: JNJ-77242113 Dose 1 Twice Daily (BID) and PlaceboExperimental Treatment2 Interventions
Participants will receive JNJ-77242113 Dose 1 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Group III: Group 3: JNJ-77242113 Dose 3 QD and PlaceboExperimental Treatment2 Interventions
Participants will receive JNJ-77242113 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Group IV: Group 2: JNJ-77242113 Dose 2 QD and PlaceboExperimental Treatment2 Interventions
Participants will receive JNJ-77242113 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Group V: Group 1: JNJ-77242113 Dose 1 Once Daily (QD) and PlaceboExperimental Treatment2 Interventions
Participants will receive JNJ-77242113 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Group VI: Group 6: PlaceboPlacebo Group1 Intervention
Participants will receive placebo BID from Week 0 through Week 16.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
JNJ-77242113
2022
Completed Phase 2
~640

Find a Location

Who is running the clinical trial?

Janssen Research & Development, LLCLead Sponsor
975 Previous Clinical Trials
6,384,053 Total Patients Enrolled
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
745 Previous Clinical Trials
3,959,650 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has JNJ-77242113 been sanctioned by the Food and Drug Administration?

"The safety of JNJ-77242113 was assigned a 2 on the 1 to 3 scale, as no data exist that demonstrates efficacy. However, there is some prior evidence indicating its safety potential."

Answered by AI

In how many locales is this research endeavor taking place?

"25 sites are currently enrolling participants in this medical trial, which span from Ocala to Rockville and Las Vegas. It is encouraged that prospective patients choose a location close to their residence so as to minimize transportation costs."

Answered by AI

Are there openings still available for this research project?

"Clinicaltrials.gov records indicate that this trial, whose record was first posted on March 2nd 2022 and last amended on October 25th 2022, is not presently selecting participants. Nevertheless, there are 167 alternative studies currently seeking enrolment."

Answered by AI

Who else is applying?

What state do they live in?
New York
Pennsylvania
How old are they?
18 - 65
What site did they apply to?
Windsor Dermatology, PC
Innovaderm Research
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
2022. "A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05223868.
~81 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top